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Rheumatoid arthritis (RA) is a chronic inflam-
matory disease leading to joint destruction (1). In RA,
migration of leukocytes into the synovial tissue (ST)
occurs. These leukocytes and other cells in the ST,
particularly RA ST fibroblasts, produce mediators of
inflammation, including chemokines (1). Chemokines,
currently numbering more than 50, are chemotactic
cytokines that are important in recruitment of leuko-
cytes and angiogenesis. They exert chemotactic activity
toward a variety of cell types (2–7). Some chemokines,
particularly CXC chemokines containing the ELR motif,
are angiogenic. The last few years have seen a rapid
development of studies aimed at targeting proinflamma-
tory chemokines or their receptors in RA and animal
models of RA (8,9). This review summarizes many of the
important developments in this field. Based on the
number of recently published studies, it is likely that the
next few years will bring several new preclinical and
clinical trials targeting chemokines.
Chemokines
Chemokines have been classified into 4 super-
gene families based on the location of cysteine residues
(Figure 1). The 4 groups are CXC, CC, C, and CX3C
chemokines (10–12). A relatively new classification sys-
tem was introduced in 2000, in which chemokines are
considered as chemokine ligands, and each chemokine
has been assigned a designation of CXCL, CCL, XCL,
or CX3CL1 (Figure 1) (10–12). In this report, both the
former and new nomenclature are noted.
CXC chemokines have 2 conserved cysteines
separated by 1 unconserved amino acid (9,13) (Figure
1). CXC chemokines classically were thought to be
involved in the chemotaxis of neutrophils. Many chemo-
kines may have arisen from reduplication of ancestral
genes (13). Hence, CXC chemokines that act on neutro-
phils are clustered on chromosome 4q12–13 (13). How-
ever, some genes of more newly discovered CXC che-
mokines that recruit lymphocytes tend to be located
away from the major clusters (13). This diversification
may reflect functional specialization. Another function
of CXC chemokines is to modulate angiogenesis
(7,14,15). In general, chemokines containing the ELR
motif, such as interleukin-8 (IL-8)/CXCL8, epithelial
neutrophil–activating peptide 78 (ENA-78)/CXCL5,
growth-related oncogene  (GRO)/CXCL1, and con-
nective tissue activating peptide III (CTAP-III)/CXCL7,
promote angiogenesis. Conversely, ELR-lacking chemo-
kines, including platelet factor 4 (PF-4)/CXCL4,
interferon-–inducible 10-kd protein (IP-10)/CXCL10,
and monokine induced by IFN (Mig)/CXCL9, inhibit
neovascularization (7,15,16). Contrary to this paradigm,
the ELR-lacking stromal cell–derived factor 1 (SDF-1)/
CXCL12 is angiogenic (5,16).
CC chemokines have adjacent cysteine residues
(Figure 1) (8,13). These chemokines classically were
thought to induce monocyte chemotaxis, although many
members of this group may also recruit other cell types
such as lymphocytes. As with CXC chemokines, many of
the genes encoding CC chemokines are clustered, in this
case on human chromosome 17q11.2 (4,8,13). Genes of
CC chemokines recruiting lymphocytes are not found in
this cluster in general.
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C chemokines and CX3C chemokines have been
described based on the position of cysteine residues
(Figure 1) (1). The C family contains lymphotactin/
XCL1 and single C motif 1 (SCM-1)/XCL2, while the
CX3C family contains fractalkine/CX3CL1.
CXC chemokines. My group and several others
have detected IL-8/CXCL8 in high quantities in the
synovial fluid (SF), ST, and sera of patients with RA
(17–20). Subsynovial macrophages, ST lining cells, and
endothelial cells express IL-8/CXCL8 (18,21,22). We
have shown that ST macrophages constitutively produce
IL-8/CXCL8 (18). Unlike macrophages, ST fibroblasts
require exogenous stimuli such as IL-1, tumor necrosis
factor  (TNF), or lipopolysaccharide (LPS) to pro-
duce IL-8/CXCL8 (18,23). Regulation of IL-8/CXCL8
production from RA ST fibroblasts appears to be con-
trolled by NF-B (24). Kraan et al showed that IL-8/
CXCL8 was increased in the involved joints compared
with the uninvolved joints of patients with RA (25). In a
study by Taylor et al, TNF blockade in patients with
RA resulted in decreased 111In-labeled granulocyte mi-
gration into affected joints as well as a reduction in the
expression of IL-8/CXCL8 in the ST (26). Chemokine
networks exist in the RA joint, so that RANTES/CCL5,
monocyte chemoattractant protein 1 (MCP-1)/CCL2, or
SDF-1/CXCL12 up-regulates RA ST fibroblast expres-
sion of IL-8/CXCL8, indicating that chemokines can
regulate the expression of other chemokines in the joint
(27). A study by Patterson et al showed binding of
labeled IL-8/CXCL8 to RA ST neutrophils (28). How-
ever, although a main function of IL-8/CXCL8 may be to
recruit neutrophils, it has been increasingly difficult to
demonstrate an association between SF neutrophil
counts and IL-8/CXCL8 levels. An alternative paradigm
may be that a prominent function of RA joint IL-8/
CXCL8 is to mediate angiogenesis. Indeed, we have
shown that IL-8/CXCL8 is a potent mediator of angio-
genesis in the RA joint (14,22).
ENA-78/CXCL5 is a chemotactic factor for neu-
trophils and is angiogenic (9,15,22,29). We have shown
Figure 1. Chemokine family classification. IL-8  interleukin-8; ENA-78 
epithelial neutrophil–activating peptide 78; Gro  growth-related oncogene ;
CTAP-III  connective tissue activating peptide III; Nap-2  neutrophil-activating
peptide 2; Mig  monokine induced by interferon- (IFN); PF4  platelet factor
4; ITAC  IFN-inducible T cell  chemoattractant; BCA-1  B cell activating
chemokine 1; SDF-1  stromal cell–derived factor 1; GCP-2  granulocyte
chemotactic protein 2; MCP-1  monocyte chemoattractant protein 1; LARC 
liver and activation-regulated chemokine; MIP-1  macrophage inflammatory
protein 1; TARC  thymus and activation–regulated chemokine; HCC-1 
hemofiltrate CC chemokine 1; PARC  pulmonary and activation-regulated
chemokine; MDC  macrophage-derived chemokine; MPIF-1  macrophage
procoagulant-inducing factor 1; CTACK  cutaneous T cell–attracting chemokine;
MEC  mucosae-associated epithelial chemokine; SCM-1  single C motif 1;
TM  transmembrane domain; Cyt  cytoplasmic domain. Adapted, with permis-
sion, from ref. 12.
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that the ENA-78 levels observed in RA SF are much
higher than those in SF from patients with osteoarthritis
(OA) (30). RA ST fibroblasts constitutively produce
ENA-78/CXCL5, and this production is augmented by
IL-1, TNF, or IL-18 (30,31). ENA-78/CXCL5 accounts
for a portion of the angiogenic activity observed in RA
ST (22).
GRO/CXCL1 is a potent neutrophil chemoat-
tractant found in RA SF and ST (17,23,32,33). GRO/
CXCL1 is inducible by TNF and IL-1 in RA ST
fibroblasts (33,34). GRO induces expression of intersti-
tial collagens by RA fibroblasts (32).
CTAP-III/CXCL7, which is derived from human
platelets (35), is angiogenic. CTAP-III/CXCL7 found in
RA ST extracts induces synthesis of glycosaminoglycans
and growth of RA ST fibroblasts (36). Cytokines such as
IL-1, basic fibroblast growth factor, and epidermal
growth factor synergize with CTAP-III/CXCL7 in induc-
ing glycosaminoglycan synthesis (36).
Granulocyte chemotactic protein 2 (GCP-2)/
CXCL6 was recently identified as being up-regulated in
RA ST fibroblasts exposed to Toll-like receptor 2
(TLR-2) ligands (37). Concentrations of GCP-2/CXCL6
were up-regulated in RA SF compared with OA SF.
IP-10/CXCL10 is up-regulated in RA SF com-
pared with OA SF (38,39). IP-10/CXCL10 serum levels
in rheumatoid factor–positive individuals were higher
than those in control (OA or trauma) patients (38).
Serum IP-10/CXCL10 levels were reported as being
similar to normal in one study (40) but increased in
another study (38). RA ST macrophages and fibroblasts
immunostain for IP-10/CXCL10, and RA ST expresses
greater amounts of IP-10/CXCL10 messenger RNA
(mRNA) than does OA ST (39,41). TWEAK (human
TNF-like weak inducer of apoptosis) induces IP-10/
CXCL10 production from RA ST fibroblasts (42).
Moreover, the adhesion molecules CD11b and CD18
and intracellular adhesion molecule 1 (ICAM-1) are
required for IP-10/CXCL10 induction on RA ST fibro-
blasts (39). Functionally lacking the ELR motif, IP-10/
CXCL10 is angiostatic (7). Overall, IP-10/CXCL10 may
recruit Th1 cells into RA ST (39).
Mig/CXCL9 levels were also elevated in RA
versus control SF and present in RA ST, particularly in
macrophages (38,43). Like IP-10/CXCL10, Mig/CXCL9
is angiostatic (7). PF-4/CXCL4 was reported to be
elevated in the serum of RA patients (44). PF-4/CXCL4
is also angiostatic (45). SDF-1/CXCL12 specifically
binds to CXCR4 and has been implicated in B cell/T
cell/monocyte recruitment into the RA ST, as well as in
mediating angiogenesis (46–50). Endothelial SDF-1/
CXCL12 is involved in SF T cell adhesion to ICAM-1
(46). SDF-1/CXCL12 plays a role in CD4 T cell
recruitment into the RA ST (49). T cells are able to
migrate beneath RA ST fibroblasts in vitro, a process
termed pseudoemperipolesis. Pseudoemperipolesis may
serve as a marker of T cell accumulation within ST (50).
Both SDF-1/CXCL12 and CXCR4 are expressed
by CD68 macrophages in the RA ST. Using a SCID
mouse engrafted with human ST in vivo, Blades et al
showed that when the graft was injected with SDF-1/
CXCL12, human U937 monocytoid cells were recruited
to the ST (48). SDF-1/CXCL12 was a more potent
stimulus for monocyte recruitment than even the potent
stimulus TNF.
SDF-1/CXCL12, despite lacking the ELR motif,
promotes angiogenesis (16,51). RA ST fibroblasts pro-
duce SDF-1/CXCL12 under hypoxic conditions. ST
fibroblast-derived SDF-1/CXCL12 accumulates and is
immobilized on heparin sulfate molecules of endothelial
cells, where it can promote angiogenesis and inflamma-
tion (52). RA plasma contains more SDF-1/CXCL12
than does control plasma (53). SDF-1/CXCL12 accounts
for a portion of the angiogenic activity observed in RA
SF, as determined by the Matrigel plug rodent in vivo
angiogenesis assay (52).
B cell recruitment has recently gained support as
a potential target in RA. Burger and coworkers showed
that RA ST fibroblasts support spontaneous migration
of B cells beneath them via an SDF-1/CXCL12 and
CD106 vascular cell adhesion molecule 1 (VCAM-1)–
dependent mechanism (47). B cell activating chemokine
1 (BCA-1/CXCL13) binds CXCR5, which is expressed
on circulating mature B cells and a subset of memory
CD4 T lymphocytes (54). Shi and colleagues (55) and
Takemura and coworkers (56) reported that BCA-1/
CXCL13 is expressed in RA ST in follicular dendritic
cells in germinal centers. Endothelial cells and fibro-
blasts in the ST also express BCA-1/CXCL13 (56).
Hence, BCA-1/CXCR5 and SDF-1/CXCL12 interac-
tions may also recruit B cells into the inflamed joint.
CC chemokines. MCP-1/CCL2 is a potent che-
moattractant for monocytes (57), and our group previ-
ously reported that MCP-1/CCL2 levels were higher in
RA SF than in OA SF (57). MCP-1/CCL2 is detectable
in the sera of RA patients. Stimuli for RA ST fibroblast
MCP-1/CCL2 production include IL-1, TNF, and IFN
(23,57–61). Hypoxia decreases IL-1–induced RA ST
fibroblast MCP-1/CCL2 induction (62). Messenger
RNA for MCP-2/CCL8 has recently been detected in
RA ST fibroblasts stimulated by TLR-2 ligands (37).
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Quantities of this chemokine were larger in RA SF than
those in OA SF.
Macrophage inflammatory protein 1 (MIP-1)/
CCL3 chemoattracts a variety of cells, including lympho-
cytes, monocytes, basophils, and eosinophils (4,8). We
previously observed that RA MIP-1/CCL3 levels were
higher than were OA SF levels (63). SF mononuclear
cells and ST fibroblasts produce MIP-1/CCL3 mRNA
and protein (23,63). MIP-1/CCL3, produced by CD44
T cells, is augmented by IL-15 stimulation (64). SF
neutrophils produce more MIP-1/CCL3 than do RA
peripheral blood neutrophils (65). MIP-1/CCL4 gene
expression was observed in RA SF T cells (66). We have
shown that TNF and IL-1 induce RA ST fibroblast
MIP-1/CCL3 production (63). MIP-1/CCL4, in con-
trast to many of the previously described chemokines,
appears to be up-regulated in OA SF compared with RA
SF (67).
MIP-3/CCL20 is a CC chemokine that chemoat-
tracts T cells, B cells, monocytes, and immature den-
dritic cells. Large amounts of MIP-3/CCL20 have been
detected in RA SF and RA ST. In RA ST, MIP-3–
producing cells were often located in proximity to im-
mature dendritic cells, suggesting the capacity to recruit
these cells (68). In the ST, mainly infiltrating macrophages
and ST lining cells expressed MIP-3/CCL20. RA ST
fibroblasts produced this chemokine in response to cyto-
kines, including TNF, IL-1, IL-17, or IL-18 (69–71).
MIP-3 is potently chemotactic for monocytes (70).
RANTES/CCL5 chemoattracts lymphocytes and
monocytes as well as other cell types (8,72,73). RA ST
fibroblasts produce RANTES/CCL5 mRNA upon stim-
ulation with TNF, IL-1, or IFN (23,73–75). Thrombin
also activates RA ST fibroblast RANTES/CCL5 produc-
tion via protease-activated receptor 1 (PAR-1) (76).
RANTES/CCL5 mRNA has also been detected in RA
peripheral blood and SF T cells, as well as in the lining
layer and macrophages in RA ST (66,73). RANTES/
CCL5, as well as MCP-1/CCL2, can participate in cyto-
kine networks by inducing RA ST fibroblasts to produce
IL-8/CXCL8 and IL-6 (27).
Lymphoid aggregates are often present in in-
flamed RA ST. Buckley recently described immunohis-
tologic expression of Epstein-Barr virus–induced gene 1
ligand chemokine (ELC)/CCL19, a B cell–attracting
chemokine, in RA ST (77). It may be that this chemo-
kine along with the CXC chemokines SDF-1/CXCL12
and BCA-1/CXCL13 contribute to B lymphocyte re-
cruitment in RA synovitis.
C and CX3C chemokines. Lymphotactin/XCL1 is
expressed in CD8 T cells and is significantly increased
in CD4,CD28 T cells from RA versus normal peri-
pheral blood (78). Blaschke et al demonstratd that in
RA ST, lymphotactin/XCL1 was mainly localized in
CD4 sublining cells (78). Incubation of lymphotacin/
XCL1 with RA ST fibroblasts resulted in down-
regulation of matrix metalloproteinase 2 (MMP-2) pro-
duction. Lymphotactin/XCL1 stimulated the
transmigration of the CD45RO/CD45RB T cells.
These T lymphocytes preferentially accumulate in vivo
in the joints of patients with RA (79).
Fractalkine/CX3CL1 plays a dual role, being
chemotactic for monocytes and lymphocytes and also
serving as a cellular adhesion molecule (80,81). Our
group has observed high levels of soluble fractalkine/
CX3CL1 in RA SF (81). In the peripheral blood and SF,
mainly monocytes expressed this chemokine. In RA ST,
macrophages, fibroblasts, endothelia, and dendritic cells
expressed fractalkine/CX3CL1 (81). Fractalkine/
CX3CL1 stimulation of RA ST fibroblasts resulted in
up-regulation of MMP-2 levels (81). Fractalkine/
CX3CL1 may contribute to the accumulation of
CX3CR T cells in RA ST (27).
Fractalkine/CX3CL1 has recently received much
attention in the field of atherosclerosis. When the
fractalkine/CX3CL1 receptor CX3CR1 was deleted in
mice, atherosclerosis development was greatly reduced
(82). Similarly, in another study in humans, a CX3CR1-
M280/I249 polymorphism was associated with reduced
cardiovascular risk (83). My laboratory has also shown
that fractalkine/CX3CL1 is angiogenic (84). Because
accelerated atherosclerosis is an integral part of RA, it is
likely that targeting fractalkine/CX3CL1 or its receptor
may be useful in cardiovascular disease as well as RA.
Chemokine receptors
Chemokines mediate their effects via 7-transmem-
brane domain receptors that are a subset of G protein–
coupled receptors (GPCRs) (13). As shown in Table 1,
there is a great deal of redundancy and binding promis-
cuity between chemokine ligands and their receptors.
Chemokine receptors have been associated with various
subtypes of autoimmune inflammation. Thus, RA, which
is considered a Th1 disease, is associated with CXCR3
and CCR5 (85,86). Conversely, asthma is considered a
Th2 disease and is associated with CCR3, CCR4, and
CCR8 (13,85).
Among CXC chemokine receptors, CXCR1 and
CXCR2 are expressed on RA macrophages and neutro-
phils (28). We and other investigators have shown
CXCR3 to be expressed in RA joints and perhaps to be
an important receptor in homing of leukocytes into the
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RA ST (85,86). CXCR3 has been shown to mark a
subset of T lymphocytes. Ruth and colleagues reported
that most T lymphocytes in RA SFs were CXCR3 (87).
CXCR3 is expressed by endothelial cells, some dendritic
cells, and T cells in the RA ST (87,88). CXCR3 has also
been found on RA ST mast cells (41). CXCR4 is present
on a variety of cell types. Transforming growth factor 1
induces CXCR4 expression on RA ST T cells (46).
Among CC chemokine receptors, CCR5 showed
strong expression on RA ST fibroblasts and ST T
lymphocytes (85). CCR5 has been shown in several
studies to be present on mononuclear cells in SF from
patients with RA (27,86,89,90). We demonstrated lym-
phocyte chemokine receptor expression in RA, which
may play a role in inflammatory cell recruitment into the
joint. Our data suggest that CCR4 and CCR5 may be
critical to this process (87).
Recently, CCRL2, which codes for a putative
7-membrane GPCR, has been identified on RA SF
neutrophils and some macrophages (91). Inflammatory
products present in RA SF activate this receptor, indi-
cating that CCRL2 may be involved in RA pathogenesis.
The gene for this receptor is located on chromosome 3,
in close proximity to other chemokine receptors.
We compared chemokine receptor expression on
peripheral blood, SF, and ST monocyte/macrophages in
RA. We observed that monocytes mainly express CCR1
and CCR2 in normal and RA peripheral blood (92). In
contrast, CCR3 and CCR5 are up-regulated in RA SF.
The differential expression of these receptors suggests
that CCR1 and CCR2 may be involved in monocyte
recruitment from the circulation, while CCR3 and
CCR5 may be important in monocyte retention in the
joint (92).
Other chemokine receptors may also be involved
in RA. CCR6, a receptor for MIP-3/CCL20, was detected
on infiltrating white blood cells in the RA ST (69). XCR1,
the lymphotactin/XCL1 receptor, was immunolocalized to
ST lymphocytes, macrophages, and fibroblasts.
Regarding CX3C chemokines, the fractalkine/
CX3CL1 receptor was present on RA SF CD3 lym-
phocytes and CD14 macrophages. In RA ST, macro-
phages and dendritic cells were the predominant cells
bearing CX3CR1 (81). CX3CR1 has been implicated in
both monocyte recruitment and lymphocyte recruitment
in the RA joint (81,93).
Chemokines may also bind to the Duffy receptor.
DARC binds both CC and CXC chemokines and was
originally described on red blood cells. A recent study
showed that RA ST endothelium expressed DARC (94).
Table 1. Human chemokine receptors*
Receptor Ligand
CXCR1 IL-8/CXCL8, GCP-2/CXCL6
CXCR2 IL-8/CXCL8, GRO/CXCL1, GRO/CXCL2, GRO/CXCL3, CTAP-III/NAP-2/CXCL7, ENA-78/CXCL5, GCP-2/CXCL6




CCR1 MIP-1/CCL3, RANTES/CCL5, MCP-3/CCL7, MIP-5; HCC-1/CCL14, HCC-2/CCL15, HCC-4/CCL16; LD78/CCL3L1,
MPIF-1/CCL23
CCR2 MCP-1/CCL2, MCP-3/CCL7, MCP-4/CCL13; HCC-4/CCL16
CCR3 Exotaxin/CCL11, exotaxin-2/CCL24, exotaxin-3/CCL26; RANTES/CCL5, MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13;
HCC-2/CCL15, MEC/CCL28
CCR4 TARC/CCL17, MDC/CCL22








DARC Duffy antigen; binds some CC and CXC chemokines
*IL-8  interleukin-8; GCP-2  granulocyte chemotactic protein 2; GRO  growth-related oncogene ; CTAP-III  connective tissue activating
peptide III; NAP-2  neutrophil-activating peptide 2; ENA-78  epithelial neutrophil–activating peptide 78; Mig  monokine induced by
interferon- (IFN); ITAC  IFN-inducible T cell  chemoattractant; PF-4  platelet factor 4; SDF-1  stromal cell–derived factor 1; BCA-1 
B cell activating chemokine 1; MIP-1  macrophage inflammatory protein 1; MCP-3  monocyte chemoattractant protein 3; HCC-1 
hemofiltrate CC chemokine 1; MPIF-1  macrophage procoagulant-inducing factor 1; MEC  mucosae-associated epithelial chemokine; TARC 
thymus and activation–regulated chemokine; MDC  macrophage-derived chemokine; SLC  secondary lymphoid tissue chemokine; TECK 
thymus-expressed chemokine; CTACK  cutaneous T cell–attracting chemokine; SCM-1  single cysteine motif 1; DARC  Duffy antigen
receptor for chemokines. Adapted, with permission, from ref. 12.
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Chemokine targeting strategies in experimental
arthritis
Temporal expression of chemokines in arthritis
models. As a prelude to determining which chemokines
to target, the temporal expression of chemokines has
been determined in animal models. For instance, ENA-
78/CXCL5, MCP-1/CCL2, and MIP-1/CCL3 were as-
sessed during the course of rat adjuvant-induced arthri-
tis (AIA), a model for human RA, in order to
differentiate between chemokines involved in the early
events or later stages of the disease (95). Levels of both
ENA-78/CXCL5 and MIP-1/CCL3 in the sera and joint
homogenates of rats showed an early increase, preceding
the onset of clinical symptoms. In contrast, MCP-1/
CCL2 appeared to be involved mainly in the later phase
of AIA (96). Another group of investigators observed
increased RANTES/CCL5 and MIP-1/CCL3 produc-
tion in murine collagen-induced arthritis (CIA) com-
pared with that in normal mice (97). Determining the
time course of chemokine expression during arthritis
development should aid in pinpointing therapeutic in-
tervention points in disease.
CXC chemokines. In the last several years, sev-
eral studies targeting chemokines or their receptors
experimentally have been published. Because a mouse
homolog of IL-8/CXCL8 has not been identified, many
of these studies were performed in rabbits. A neutraliz-
ing antibody to IL-8/CXCL8 prevented neutrophil infil-
tration into rabbit LPS/IL-1–induced arthritis (98). Sim-
ilarly, an antibody to IL-8/CXCL8 inhibited LPS- or
monosodium urate crystal–induced leukocyte infiltra-
tion into rabbit knee joints (99,100). A nonpeptide oral
antagonist of the IL-8/CXCL8 receptor, CXCR2, inhib-
ited acute IL-8/CXCL8– or LPS-induced arthritis and
chronic antigen (ovalbumen)-induced arthritis in rabbits
(101). In LPS-induced rabbit arthritis, elevated SF GRO
levels preceded knee joint leukocyte infiltration, which
was inhibited 54% by GRO-specific neutralizing anti-
body, 48% by anti–IL-8, and 70% by a combination of
both antibodies (102).
Preventative anti–MIP-2/GRO/CXCL1 in a
mouse homolog resulted in delayed onset and severity of
murine CIA (96). Finally, AMD3100, an antagonist of
the SDF-1/CXCL12 receptor CXCR4, inhibited CIA
preventively and therapeutically in IFN-deficient
DBA/1 mice (103). Matthys et al used IFN-deficient
DBA/1 mice in order to hasten the course of CIA
compared with that in non–cytokine-deficient animals.
Thus, these data suggest that targeting CXC chemokines
and their receptors may have an impact on experimental
arthritis and potentially on RA.
In an interesting study, Salomon et al adminis-
tered IP-10/CXCL10 naked DNA vaccine to rats in-
duced to develop AIA (104). Rats developed protective
immunity against AIA. Moreover, self-specific anti–IP-
10/CXCL10 or rabbit anti-rat IP-10/CXCL10 adoptively
transferred disease suppression. These results suggest
IP-10/CXCL10 may be a target in RA.
In another study, my laboratory used an anti–
ENA-78/CXCL5 polyclonal antibody strategy preven-
tively in rat AIA. The severity of AIA was attenuated, as
determined by joint swelling and circumference. This
antibody was unable to reverse the disease course when
injected during the further development of arthritis,
suggesting that to be effective, antibody must be given
early in the course of arthritis development (105).
PF-4/CXCL4 is angiostatic and inhibits endothe-
lial cell proliferation (106). An antiinflammatory pep-
tide of PF-4/CXCL4 successfully inhibited mouse CIA
when administered therapeutically (106). Although the
mechanism of action of this peptide was unclear, inter-
estingly, circulating IL-1 levels decreased with treat-
ment. Hence, unlike most of the other published studies,
in the study by Wooley et al, administration of a
chemokine rather than blocking of a chemokine’s ac-
tions was beneficial. Although not examined in this
study, the angiostatic role of PF-4/CXCL4 may have
played a role in the effect of this chemokine on CIA,
because other angiogenesis inhibitors are effective in
this model.
Very few studies have examined arthritis in gene-
deficient mice. However, Terkeltaub and coworkers
observed that CXCR2 gene–deficient mice exhibited
leukocyte-deficient inflammatory responses in a murine
subcutaneous air pouch model injected with urate crys-
tals (107). These same animals showed less severe Lyme
arthritis than did normal mice in another study (108).
Because mice, in contrast to humans, express only
CXCR2, not both CXCR1 and CXCR2, the relevance to
human disease of deleting only CXCR2 remains unclear.
CC chemokines. A number of studies have tar-
geted MIP-1/CCL3 and MCP-1/CCL2. Passive immu-
nization with anti–MIP-1/CCL3 delayed the onset and
reduced the severity of murine CIA (96). A 67–amino
acid sequence of MCP-1/CCL2, which acts as an MCP-
1/CCL2 antagonist in vivo, abrogated arthritis in MRL/
lpr autoimmune mice (109). Injection of neutralizing
MCP-1/CCL2 resulted in reduced macrophage numbers
and arthritis in rats with CIA (110). Bindarit, an inda-
zolic derivative inhibitor of TNF and MCP-1/CCL2,
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inhibited rat AIA (111). Injection of anti–MCP-1/CCL2
preventively resulted in decreased influx of 111In-labeled
T cells into the rat streptococcal cell wall antigen–
induced arthritic joint (112).
Administration of Met-RANTES, a CCR1/CCR5
antagonist, reduced mouse CIA (113). Likewise, anti-
RANTES/CCL5 reduced mouse CIA (114). A CCR5
nonpeptide antagonist, when used preventively, inhib-
ited mouse CIA and migration of leukocytes to the joints
(115). This inhibitor, however, also blocked binding of
ligand to CXCR3, making it difficult to determine its
precise mechanism (116). KE-298 (2-acetylthiolmethyl-
4-[4-methylphenyl]-4-oxobutanoic acid), an antirheu-
matic drug, reduced MCP-1/CCL2 and RANTES/CCL5
production and also reduced the severity of rat AIA
(117). This drug also suppressed production of these
chemokines by IL-1– stimulated RA ST fibroblasts. Very
surprisingly, a recent study showed that a CCR5 gene–
deficient mouse developed CIA to the same extent as
wild-type mice (118). The reason for the discrepant data
using CCR5-deficient mice is unclear. Nonetheless, most
available data in other models appear to indicate CCR5
is a reasonable therapeutic target in RA.
Manipulation of the CCR2 receptor has pro-
duced varied outcomes. Antibody-mediated blockade of
CCR2 during initiation of CIA in mice resulted in
markedly improved clinical signs of arthritis, while
blockade during disease progression (therapeutic ad-
ministration) worsened the clinical and histologic signs
of arthritis (119). Moreover, in a recent study, CCR2
gene–deficient mice developed severe, aggressive CIA
compared with wild-type mice (118). Interestingly, when
lethally irradiated wild-type mice received bone marrow
transplants from CCR2 gene–deficient mice, the trans-
planted mice developed frank CIA. In contrast, wild-
type mice transplanted with wild-type bone marrow did
not develop CIA, suggesting that the expression of
CCR2 in the hematopoetic compartment is a critical
component of CIA development (118). Hence, it ap-
pears that targeting CCR1/CCR5 may be useful in
experimental arthritis. Results for CCR2 blockade are
much less clear at this time and await further studies.
My laboratory has examined chemokine receptor
expression and function in rat AIA (120). Using real-
time polymerase chain reaction, we showed significant
up-regulation of CCR1, CCR2, CCR5, and MIP-1/
CCL4 mRNA on postadjuvant injection day 18, coinci-
dent with peak joint inflammation. Increases in tyrosine
phosphorylation of CCR1 on days 14, 18, 21, and 24, of
CCR2 on days 14 and 18, and of CCR5 on days 14, 18,
and 21 were observed in rats with AIA compared with
nonarthritic rats. The joint signaling intermediates,
JAK-1, signal transducer and activator of transcription 1
(STAT-1), and STAT-3, were associated with CCR1 and
were tyrosine phosphorylated on days 14 and 18. CCR2
was associated with phosphorylated JAK-2, STAT-1,
and STAT-3 on day 18. CCR5 was associated with
STAT-1 and STAT-3 on days 18 and 21 and correlated
with JAK-1 phosphorylation and binding on day 18.
Although JNK signaling has been shown by other inves-
tigators to be important in RA synovium, it appears not
to be important in CCR5 signaling in rat AIA joints. By
immunohistologic analysis, CCR5, phosphorylated
STAT-1, and phosphorylated STAT-3 were detected on
ST lining cells, macrophages, and endothelial cells in
inflamed rat joints on day 18. Although the majority of
Figure 2. Hypothesized CC chemokine receptor signaling in joints of rats with
adjuvant-induced arthritis. STAT1  signal transducer and activator of transcrip-
tion 1.
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phosphorylated STAT-1 and CCR5 were on ST lining
cells and macrophages, phosphorylated STAT-3 was
predominantly expressed on endothelial cells (see Fig-
ure 2). Up-regulation and activation of chemokine re-
ceptors may play a role in macrophage and endothelial
infiltration in rat AIA joints.
Combined chemokine blockade. Several studies
have addressed the blocking of multiple chemokines.
One study showed that a combination of MCP-1/CCL2
and GRO/CXCL1 inhibition with chemokine antago-
nists resulted in more reduced arthritis than MCP-1/
CCL2 blockade alone in MRL-Faslpr mice with AIA
(121). In another study, rat AIA was diminished by DNA
vaccination with chemokine-encoding DNA vaccines to
MCP-1/CCL2, MIP-1/CCL3, or RANTES/CCL5 (122).
These studies do not address the possible toxicities
associated with combining blocking agents, which poten-
tially could be problematic in human trials.
Chemokine targeting strategies in human RA
As a prelude to chemokine targeting in humans,
one study has shown decreased severity and incidence of
RA in patients with the CCR5 32 allele, which codes
for a nonfunctional CCR5 allele (123,124). Another study
showed that this allele was found less frequently in patients
with RA (125). These studies underscore the idea that
targeting CCR5 in humans may be beneficial in RA.
Regarding direct targeting, antibodies to IL-8/
CXCL8, ENA-78/CXCL5, and GRO/CXCL1 at least
partially neutralized RA SF–derived chemotactic activ-
ity for neutrophils in vitro, and antibodies to MIP-1
neutralized RA SF-derived chemotactic activity for
monocytes (33,67). Among drugs currently available for
RA therapy, anti-TNF reduced synovial expression of
IL-8/CXCL8 and MCP-1/CCL2 in patients with RA (26).
One trial examined the use of anti–IL-8/CXCL8
in human RA. Results of this trial were not published,
but the compound was apparently not developed fur-
ther. Because no published data exist, it is difficult to
comment on this therapeutic agent.
Recently, a CCR1 small molecule antagonist was
examined in a phase Ib 2-week study. This inhibitor
resulted in a marked decrease in ST macrophages
posttherapy (126). Although this study was designed
mainly to examine the effect of the inhibitor on RA
synovial inflammation, one-third of the 16 patients ful-
filled the American College of Rheumatology 20%
criteria (127) for improvement after therapy. These
results suggest CCR1 may be a beneficial target in RA.
Conclusion
Although superficially one may conclude that
blocking chemokines or their receptors is futile due to
redundancies in the chemokine/chemokine receptor sys-
tems, careful analysis suggests that blockade of specific
chemokine/chemokine receptors may be valuable. How-
ever, several caveats must be considered. First, as with
many animal models, there are more reports of animal
studies using preventative regimens than reports of
studies using therapeutic regimens, as would be used in
RA patients, again lessening the relevance to human
disease. Second, many compounds targeting chemokine
receptors are species specific, hence resulting in difficul-
ties translating these compounds to human use. Third,
cleavage of some chemokines by metalloproteinases may
result in antagonist rather than agonist effects on their
receptors, potentially making targeting of chemokines
difficult. Nonetheless, after reviewing the existing data,
it seems that there is sound rationale for targeting CXC
chemokines, CC chemokines, and fractalkine/CX3CL1.
Among chemokine receptors, CXCR3 and CCR5 ap-
pear to be likely target candidates. Preliminary results
from a small human trial involving targeting CCR1 were
promising. Thus, evidence is mounting that targeting
chemokines may be useful therapy, either alone or
adjunctively, in RA.
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